OncLive TV

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, advises how to navigate therapy for patients with HER2-positive breast cancer.

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses biosimilars in the context of global cancer care.

Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses genomic characterization of muscle invasive bladder cancer histology to predict therapy response.

Maha H. Hussain, MD, FACP, Genevieve Teuton Professor of Medicine, deputy director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the potential of enzalutamide in prostate cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses selecting patients with estrogen receptor (ER)-positive breast cancer for treatment with CDK4/6 inhibitors.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the results of single-agent venetoclax (Venclexta) in patients with relapsed/refractory mantle cell lymphoma.

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the OPTIMISMM and ELOQUENT-3 trials in patients with relapsed/refractory multiple myeloma.

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Medicine, The University of Texas MD Anderson Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.

Scott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, discusses axillary node dissection in patients with early-stage breast cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the impact of biosimilars in the treatment of patients with breast cancer.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.